ATE518967T1 - Verfahren zur verhinderung einer virus-zelle- fusion durch hemmen der funktion des fusionsinitiierungsbereichs in rna-viren mit klasse-i-membranfusogenen hüllproteinen - Google Patents
Verfahren zur verhinderung einer virus-zelle- fusion durch hemmen der funktion des fusionsinitiierungsbereichs in rna-viren mit klasse-i-membranfusogenen hüllproteinenInfo
- Publication number
- ATE518967T1 ATE518967T1 AT04810256T AT04810256T ATE518967T1 AT E518967 T1 ATE518967 T1 AT E518967T1 AT 04810256 T AT04810256 T AT 04810256T AT 04810256 T AT04810256 T AT 04810256T AT E518967 T1 ATE518967 T1 AT E518967T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion
- present
- viruses
- class
- membrane
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 5
- 230000004927 fusion Effects 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 2
- 239000012528 membrane Substances 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 241000712891 Arenavirus Species 0.000 abstract 1
- 241000711573 Coronaviridae Species 0.000 abstract 1
- 241000711950 Filoviridae Species 0.000 abstract 1
- 102000018897 Membrane Fusion Proteins Human genes 0.000 abstract 1
- 108010027796 Membrane Fusion Proteins Proteins 0.000 abstract 1
- 210000000805 cytoplasm Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 241001493065 dsRNA viruses Species 0.000 abstract 1
- 238000007499 fusion processing Methods 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000000977 initiatory effect Effects 0.000 abstract 1
- 230000002452 interceptive effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/18—Testing for antimicrobial activity of a material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56988—HIV or HTLV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18422—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18433—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- AIDS & HIV (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51718103P | 2003-11-04 | 2003-11-04 | |
| PCT/US2004/036578 WO2005044992A2 (en) | 2003-11-04 | 2004-11-03 | Fusion initiation region in rna virus envelope proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE518967T1 true ATE518967T1 (de) | 2011-08-15 |
Family
ID=34572923
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04810256T ATE518967T1 (de) | 2003-11-04 | 2004-11-03 | Verfahren zur verhinderung einer virus-zelle- fusion durch hemmen der funktion des fusionsinitiierungsbereichs in rna-viren mit klasse-i-membranfusogenen hüllproteinen |
Country Status (12)
| Country | Link |
|---|---|
| US (5) | US7491793B2 (https=) |
| EP (7) | EP2261377B1 (https=) |
| JP (1) | JP5008398B2 (https=) |
| AT (1) | ATE518967T1 (https=) |
| AU (2) | AU2004288218B2 (https=) |
| BR (1) | BRPI0416187A (https=) |
| CA (1) | CA2544848C (https=) |
| DK (7) | DK2261376T3 (https=) |
| ES (7) | ES2372633T3 (https=) |
| PL (4) | PL2261378T3 (https=) |
| PT (4) | PT2261378E (https=) |
| WO (1) | WO2005044992A2 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2372633T3 (es) | 2003-11-04 | 2012-01-25 | The Administrators Of The Tulane Educational Fund | Procedimiento de evitar condensación de virus: células inhibiendo la función de la región de iniciación de condensación en los virus arn que tienen proteínas de envoltura fusogénicas de membrana de clase i. |
| US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
| US8222204B2 (en) * | 2006-05-03 | 2012-07-17 | The Administrators of the Tulane Educational Fund and Autoimmune Technologies, LLC | Influenza inhibiting compositions and methods |
| PT2170365T (pt) * | 2007-06-25 | 2016-07-12 | Autoimmune Tech Llc | Composições e métodos inibidores de influenza |
| WO2009005783A1 (en) * | 2007-06-28 | 2009-01-08 | Blanchette Rockefeller Neurosciences Institute | Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis |
| US20110305749A1 (en) * | 2008-08-28 | 2011-12-15 | Mogens Ryttergaard Duch | HIV-1 Envelope Polypeptides for HIV Vaccine |
| WO2010117786A1 (en) | 2009-03-30 | 2010-10-14 | Mount Sinai School Of Medicine Of New York University | Influenza virus vaccines and uses thereof |
| US10138276B2 (en) | 2009-09-30 | 2018-11-27 | Signablok, Inc. | Inhibition of TCR signaling with peptide variants |
| WO2011077093A1 (en) * | 2009-12-22 | 2011-06-30 | Aarhus Universitet | Bivalent molecules for hiv entry inhibition |
| CN102939101A (zh) | 2010-01-26 | 2013-02-20 | 科罗拉多大学董事会，法人 | 用于通用疫苗的流感病毒组合物和方法 |
| EP2536425B1 (en) * | 2010-02-18 | 2019-06-19 | Icahn School of Medicine at Mount Sinai | Vaccines for use in the prophylaxis and treatment of influenza virus disease |
| CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| WO2012045001A2 (en) * | 2010-09-30 | 2012-04-05 | Vanderbilt University | Influenza virus antibodies and immunogens and uses therefor |
| US9060972B2 (en) * | 2010-10-30 | 2015-06-23 | George Dacai Liu | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same |
| EP4241785B1 (en) | 2011-09-20 | 2026-01-28 | Icahn School of Medicine at Mount Sinai | Influenza virus vaccines and uses thereof |
| US9969794B2 (en) | 2012-05-10 | 2018-05-15 | Visterra, Inc. | HA binding agents |
| SG11201504728RA (en) | 2012-12-18 | 2015-07-30 | Icahn School Med Mount Sinai | Influenza virus vaccines and uses thereof |
| US8999925B2 (en) * | 2013-02-26 | 2015-04-07 | The Administrators Of The Tulane Educational Fund | Arenavirus inhibiting peptides and uses therefor |
| US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
| US9649375B2 (en) * | 2013-03-14 | 2017-05-16 | The Administrators Of The Tulane Educational Fund | Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith |
| US10189878B2 (en) | 2014-09-24 | 2019-01-29 | University Of Utah Research Foundation | Ebolavirus pre-hairpin intermediate mimics and methods of use |
| US10736956B2 (en) | 2015-01-23 | 2020-08-11 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
| EP3374390A1 (en) | 2015-11-13 | 2018-09-19 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| AU2017222564A1 (en) | 2016-02-24 | 2018-09-06 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
| MX2018015755A (es) | 2016-06-15 | 2019-08-29 | Icahn School Med Mount Sinai | Proteinas de hemaglutinina de virus de influenza y usos de las mismas. |
| US11254733B2 (en) | 2017-04-07 | 2022-02-22 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| US11690907B2 (en) | 2018-06-12 | 2023-07-04 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
| US11696948B2 (en) | 2018-06-12 | 2023-07-11 | Kbio Holdings Limited | Vaccines formed by virus and antigen conjugation |
| CA3104297A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Mosaic influenza virus hemagglutinin polypeptides and uses thereof |
| US11230593B2 (en) | 2019-03-25 | 2022-01-25 | Visterra, Inc. | Compositions and methods for treating and preventing influenza |
| US12545718B2 (en) | 2019-04-24 | 2026-02-10 | Icahn School Of Medicine At Mount Sinai | Anti-influenza B virus neuraminidase antibodies and uses thereof |
| JP2022551813A (ja) * | 2019-09-04 | 2022-12-14 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | 麻疹に対する併用抗ウイルス療法 |
| US11479582B2 (en) | 2020-10-16 | 2022-10-25 | King Faisal University | Anti-SARS-CoV-2 fusion peptides |
| JP7598538B2 (ja) * | 2021-01-29 | 2024-12-12 | 東亞合成株式会社 | ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用 |
| CN117396492A (zh) * | 2021-03-30 | 2024-01-12 | 贝勒医学院 | 用于基于多肽的高效蛋白抑制的方法和组合物 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1711888A (en) * | 1987-04-24 | 1988-12-02 | Biogen, Inc. | Immunotherapeutic methods and compositions |
| US5747239A (en) * | 1990-02-16 | 1998-05-05 | United Biomedical, Inc. | Synthetic peptides specific for the detection of antibodies to HCV, diagnosis of HCV infection and preventions thereof as vaccines |
| US5567805A (en) * | 1990-03-09 | 1996-10-22 | Administrators Of The Tulane Educational Fund | The cellular receptor for the CS3 peptide of human immunodeficiency virus |
| WO1994017826A1 (en) * | 1993-02-01 | 1994-08-18 | Smithkline Beecham Corporation | Vaccinal polypeptides |
| US5464933A (en) | 1993-06-07 | 1995-11-07 | Duke University | Synthetic peptide inhibitors of HIV transmission |
| US6479055B1 (en) * | 1993-06-07 | 2002-11-12 | Trimeris, Inc. | Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission |
| US6037348A (en) * | 1996-02-09 | 2000-03-14 | Eli Lilly And Company | Inhibition of viral replication |
| JPH11209281A (ja) * | 1998-01-21 | 1999-08-03 | Daikin Ind Ltd | ヘマグルチニン結合活性及びシアリダーゼ活性に対する阻害剤、及び、これを用いてウイルス又は微生物の感染を治療及び／又は予防する方法 |
| IL127331A0 (en) | 1998-11-30 | 1999-09-22 | Yeda Res & Dev | Peptide-based vaccine for influenza |
| EP1167382A1 (en) * | 1999-03-31 | 2002-01-02 | Otsuka Pharmaceutical Co., Ltd. | Influenza virus hemagglutinin-binding peptides |
| US6750008B1 (en) | 1999-07-09 | 2004-06-15 | Trimeris, Inc. | Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission |
| AU7089600A (en) * | 1999-08-30 | 2001-03-26 | U.S. Army Medical Research Institute Of Infectious Diseases | Monoclonal antibodies and vaccines against epitopes on the ebola virus glycoprotein |
| US6605427B2 (en) * | 2000-02-10 | 2003-08-12 | Panacos Pharmaceuticals, Inc. | Assay for detection of viral fusion inhibitors |
| GB0022969D0 (en) | 2000-09-19 | 2000-11-01 | Chiron Spa | Influenza a virus subtype H16 |
| JP5180422B2 (ja) * | 2000-09-22 | 2013-04-10 | ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ | Ｈｉｖ浸入のペプチドインヒビター |
| US7731975B2 (en) * | 2001-01-31 | 2010-06-08 | The United States Of America As Represented By The Secretary Of The Army | Chimeric filovirus glycoprotein |
| US7452963B2 (en) * | 2001-03-27 | 2008-11-18 | Samuel Bogoch | Replikin peptides and antibodies therefore |
| US7774144B2 (en) * | 2001-10-26 | 2010-08-10 | Samuel Bogoch | System and method for identifying complex patterns of amino acids |
| KR100906102B1 (ko) * | 2001-03-27 | 2009-07-07 | 사무엘 보고치 | 레플리킨 펩타이드 및 그의 이용 |
| US7189800B2 (en) * | 2001-03-27 | 2007-03-13 | Samuel Bogoch | Replikin peptides in rapid replication of glioma cells and in influenza epidemics |
| US7894999B2 (en) * | 2001-03-27 | 2011-02-22 | Samuel Bogoch | Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds |
| US7420028B2 (en) * | 2001-03-27 | 2008-09-02 | Samuel Bogoch | Replikins and methods of identifying replikin-containing sequences |
| US7442761B2 (en) * | 2003-06-06 | 2008-10-28 | Samuel Bogoch | Replikin peptides and uses thereof |
| JP4651213B2 (ja) * | 2001-03-27 | 2011-03-16 | 株式会社グライコメディクス | インフルエンザウイルス・ヘマグルチニン結合性ペプチド |
| WO2004002415A2 (en) * | 2002-06-27 | 2004-01-08 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating a cytotoxic t lymphocyte immune response |
| US20070092936A1 (en) * | 2003-05-08 | 2007-04-26 | Haynes Barton F | Severe acute respiratory syndrome |
| EP1633775A2 (en) * | 2003-06-13 | 2006-03-15 | Crucell Holland B.V. | Antigenic peptides of sars coronavirus and uses thereof |
| TW200510450A (en) * | 2003-07-21 | 2005-03-16 | Nat Inst Health | Soluble fragments of the SARS-CoV spike glycoprotein |
| ES2372633T3 (es) | 2003-11-04 | 2012-01-25 | The Administrators Of The Tulane Educational Fund | Procedimiento de evitar condensación de virus: células inhibiendo la función de la región de iniciación de condensación en los virus arn que tienen proteínas de envoltura fusogénicas de membrana de clase i. |
-
2004
- 2004-11-03 ES ES04810256T patent/ES2372633T3/es not_active Expired - Lifetime
- 2004-11-03 ES ES10182018T patent/ES2400456T3/es not_active Expired - Lifetime
- 2004-11-03 EP EP10182049.6A patent/EP2261377B1/en not_active Expired - Lifetime
- 2004-11-03 BR BRPI0416187-4A patent/BRPI0416187A/pt not_active Application Discontinuation
- 2004-11-03 ES ES10182056.1T patent/ES2437858T3/es not_active Expired - Lifetime
- 2004-11-03 PT PT101820561T patent/PT2261378E/pt unknown
- 2004-11-03 EP EP10182060.3A patent/EP2261380B1/en not_active Expired - Lifetime
- 2004-11-03 EP EP10181974A patent/EP2261374B1/en not_active Expired - Lifetime
- 2004-11-03 DK DK10182040.5T patent/DK2261376T3/da active
- 2004-11-03 AT AT04810256T patent/ATE518967T1/de active
- 2004-11-03 ES ES10182049T patent/ES2435941T3/es not_active Expired - Lifetime
- 2004-11-03 AU AU2004288218A patent/AU2004288218B2/en not_active Ceased
- 2004-11-03 ES ES10181974T patent/ES2392891T3/es not_active Expired - Lifetime
- 2004-11-03 DK DK10181974.6T patent/DK2261374T3/da active
- 2004-11-03 PL PL10182056T patent/PL2261378T3/pl unknown
- 2004-11-03 CA CA2544848A patent/CA2544848C/en not_active Expired - Fee Related
- 2004-11-03 DK DK10182060.3T patent/DK2261380T3/da active
- 2004-11-03 DK DK10182018.1T patent/DK2261375T3/da active
- 2004-11-03 US US10/578,013 patent/US7491793B2/en not_active Expired - Lifetime
- 2004-11-03 EP EP10182018A patent/EP2261375B1/en not_active Expired - Lifetime
- 2004-11-03 PT PT101820496T patent/PT2261377E/pt unknown
- 2004-11-03 EP EP10182056.1A patent/EP2261378B1/en not_active Expired - Lifetime
- 2004-11-03 EP EP10182040.5A patent/EP2261376B1/en not_active Expired - Lifetime
- 2004-11-03 DK DK10182049.6T patent/DK2261377T3/da active
- 2004-11-03 PT PT101820405T patent/PT2261376E/pt unknown
- 2004-11-03 PL PL10182040T patent/PL2261376T3/pl unknown
- 2004-11-03 EP EP04810256A patent/EP1692265B1/en not_active Expired - Lifetime
- 2004-11-03 DK DK04810256.0T patent/DK1692265T3/da active
- 2004-11-03 PL PL10182049T patent/PL2261377T3/pl unknown
- 2004-11-03 PT PT04810256T patent/PT1692265E/pt unknown
- 2004-11-03 ES ES10182060T patent/ES2427847T3/es not_active Expired - Lifetime
- 2004-11-03 WO PCT/US2004/036578 patent/WO2005044992A2/en not_active Ceased
- 2004-11-03 ES ES10182040T patent/ES2425600T3/es not_active Expired - Lifetime
- 2004-11-03 PL PL04810256T patent/PL1692265T3/pl unknown
- 2004-11-03 DK DK10182056.1T patent/DK2261378T3/da active
- 2004-11-03 JP JP2006538450A patent/JP5008398B2/ja not_active Expired - Fee Related
-
2009
- 2009-02-17 US US12/378,558 patent/US20090264362A1/en not_active Abandoned
-
2010
- 2010-03-18 AU AU2010201046A patent/AU2010201046B2/en not_active Ceased
-
2012
- 2012-05-29 US US13/482,388 patent/US8598116B2/en not_active Expired - Fee Related
-
2013
- 2013-08-08 US US13/962,524 patent/US9056900B2/en not_active Expired - Lifetime
-
2015
- 2015-05-13 US US14/711,364 patent/US9725487B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE518967T1 (de) | Verfahren zur verhinderung einer virus-zelle- fusion durch hemmen der funktion des fusionsinitiierungsbereichs in rna-viren mit klasse-i-membranfusogenen hüllproteinen | |
| NZ598000A (en) | Composition for treating hbv infection | |
| Alabi et al. | High‐throughput sequence analysis of small RNA s in grapevine (V itis vinifera L.) affected by grapevine leafroll disease | |
| NO20070194L (no) | Fremgangsmater for behandling av hepatitt C | |
| ATE540116T1 (de) | Antivirale antisense-verbindungen und verfahren zur behandlung von filovirus-infektionen | |
| US20120100527A1 (en) | Method of detecting h5 or h7 avian influenza virus | |
| DE602005025751D1 (de) | Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle | |
| EP1623012A4 (en) | ANTISENSE ANTIVIRUS AGENTS AND METHOD FOR TREATING SSRNA VIRUS INFECTION | |
| EP1507791A4 (en) | ANTISENSE ANTIVIRUS AGENTS AND METHOD FOR TREATING SSRNA VIRUS INFECTION | |
| DE602007006457D1 (de) | Antivirale antisense-verbindung und verfahren zur behandlung von arenavirus-infektion | |
| WO2022063986A3 (en) | Synthetic viruses | |
| AU2021288648A8 (en) | Conjugate of double-stranded siRNA analogue | |
| NO20062967L (no) | Mutert virus, fremgangsmate for fremstilling, og anvendelse av samme | |
| WO2014145968A2 (en) | Rna interference functions as an antiviral immunity in mammals | |
| PH12022553394A1 (en) | Conjugate of double-stranded sirna analogue | |
| US20050260166A1 (en) | Expressional enhancers from viruses | |
| ATE431162T1 (de) | Verfahren zur inaktivierung von viren durch trockene hitze | |
| Radoshitzky et al. | A Small Stem Loop Structure Of The Ebola Virus Trailer Is Essential For Replication And Interacts With Heat Shock Protein A8 | |
| Garcia-Dorival | Investigation of the interaction between Ebola virus and the host | |
| Theriault | The role of reverse genetics systems in the study of filovirus pathogenicity | |
| TW200738626A (en) | Methods for treating hepatitis C |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1692265 Country of ref document: EP |